Citrin deficiency mimicking mitochondrial depletion syndrome

S. C. Grünert 1*, A. Schumann 1, P. Freisinger 1, S. Rosenbaum-Fabian 1, M. Schmidts 1, A. J. Mueller 3, S. Beck-Wödl 3, T. B. Haack 3,4, H. Schneider 1, H. Fuchs 1, U. Teufel 1, G. Gramer 5, L. Hannibal 6 and U. Spiekerkoetter 1

Abstract

Background: Neonatal intrahepatic cholestasis caused by citrin deficiency (CD) is a rare inborn error of metabolism due to variants in the SLC25A13 gene encoding the calcium-binding protein citrin. Citrin is an aspartate-glutamate carrier located within the inner mitochondrial membrane.

Case presentation: We report on two siblings of Romanian-Vietnamese ancestry with citrin deficiency. Patient 1 is a female who presented at age 8 weeks with cholestasis, elevated lactate levels and recurrent severe hypoglycemia. Diagnosis was made by whole exome sequencing and revealed compound heterozygosity for the frameshift variant c.852_855del, p.Met285Profs*2 and a novel deletion c.(69 + 1_70 – 1)_(212 + 1_231 – 1)del in SLC25A13. The girl responded well to dietary treatment with a lactose-free, MCT-enriched formula. Her younger brother (Patient 2) was born 1 year later and also found to be carrying the same gene variants. Dietary treatment from birth was able to completely prevent clinical manifestation until his current age of 4.5 months.

Conclusions: As CD is a well-treatable disorder it should be ruled out early in the differential diagnosis of neonatal cholestasis. Due to the combination of hepatopathy, lactic acidosis and recurrent hypoglycemia the clinical presentation of CD may resemble hepatic mitochondrial depletion syndrome.

Keywords: Citrin deficiency, Neonatal cholestasis, Hypoglycemia, Newborn screening, Urea cycle defect, SLC25A13

Background

Citrin deficiency (CD) is an autosomal recessive inborn error of metabolism caused by variants in the SLC25A13 gene [1–3]. Citrin is an aspartate-glutamate carrier located within the inner mitochondrial membrane and mainly expressed in the liver, kidney, heart and small intestine [4, 5]. Its role to transport aspartate from the mitochondrial matrix to the cytosol is important for several metabolic pathways including protein, nucleotide and urea synthesis as well as gluconeogenesis from lactate and the translocation of cytosolic NADH reducing equivalents into the mitochondria via the malate-aspartate shuttle [4]. While CD is relatively common in East Asian populations, especially in Japan, the incidence in Europe is extremely low [2], although CD is a pan-ethnic disease, and subjects have been reported from different ethnicities [6–10]. Three age-dependent clinical phenotypes are associated with CD, namely 1) neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) usually manifesting in newborns or infants, 2) failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), beyond age 1 year and 3) citrullinemia type II (CTLN2) with usually sudden manifestation between ages 20 and 50 years [2]. Children with NICCD often have a history of low birth weight with growth retardation. The disease is clinically characterised by intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, variable liver dysfunction, hypoprotenemia, coagulopathy due to impaired hepatic synthesis of coagulation factors, and maternal and prenatal complications [1–3].

* Correspondence: sarah.gruenert@uniklinik-freiburg.de
1 Department of General Paediatrics, Adolescent Medicine and Neonatology, Medical Centre-University of Freiburg, Faculty of Medicine, Mathildenstraße 1, 79106 Freiburg, Germany
Full list of author information is available at the end of the article
factors, haemolytic anemia and hypoglycemia [2, 11, 12].
NICCD is generally not severe, however, few patients re-
quired liver transplantation [13, 14], and fatal cases have
been reported [15]. Many patients display markedly ele-
vated galactose levels at the age of 1 month and the use
of lactose-free milk should be considered in patients
with hypergalactosemia [16]. Dietetic treatment with use
of medium-chain triglyceride- (MCT-) enriched formul-
as has also been recommended [2, 16]. Interestingly,
children with CD show a strong preference for protein-
rich and lipid-rich foods and a natural aversion to sugar-
and carbohydrate-rich foods [4, 16, 17]. Some patients
with NICCD develop FTTDCD beyond the neonatal peri-
od and/or citrullinemia type II in adulthood, while
the majority remains asymptomatic in later life [18].
Herein we report on two siblings, of whom the first was
diagnosed immediately after birth. Both children responded well to dietary treat-
ment. The younger brother was diagnosed immediately
with NICCD develop FTTDCD beyond the neonatal peri-
od and/or citrullinemia type II in adulthood, while
the majority remains asymptomatic in later life [18].
Herein we report on two siblings, of whom the first was
diagnosed immediately after birth. Both children responded well to dietary treat-
ment. The younger brother was diagnosed immediately

**Case presentations**

**Patient 1**

The patient is the second child of non-consanguineous
parents. The father is of Vietnamese origin, the mother
of Romanian ancestry. The 2-year-old sister is healthy.
The girl was born at 38 gestational weeks after an un-
eventful pregnancy. Her birth weight was 2770 g, birth
length 48 cm, and head circumference 32 cm, Apgar
10/10. The family was discharged from hospital on day 4,
but the girl presented again on day 8 with neonatal ic-
terus (total bilirubin 21.2 mg/dl, direct bilirubin 0.8 mg/
dl) requiring phototherapy. Apart from hyperbilirubine-
mia the clinical condition was very good, and the girl
was fully breastfed. Phototherapy could be terminated
after 23 h and bilirubin levels remained stable thereafter.

At the age of 8 weeks the child presented to the local pediatrician with a mild febrile airway infection. The girl
was severely icteric but otherwise still in good clinical con-
dition. The mother reported that the child required feeding
every other hour, also at night. No stool or urine abnormalities were observed. She was admitted to the hospital
for further diagnostic work-up. Laboratory testing revealed hepatopathy with the following parameters:
prothrombin time 40%, INR 1.64, partial thromboplastin
time 41 s, fibrinogen 63 mg/dL (normal 130–330 mg/
dl), antithrombin 35%, AST 86 U/L (normal 10–35 U/
L), ALT 28 U/L (normal 10–35 U/L), alkaline phosphat-
ase 1367 U/L (normal < 449 U/L), gamma-GT 149 U/L
(8–178 U/L), total bilirubin 10.2 mg/dL (normal < 1 mg/
dl), direct bilirubin 4.9 mg/dL (normal < 0.3 mg/dL), total
protein 4.0 g/dL (normal 4.4–7.6 g/dL), albumin 2.7 g/dL
(normal 3.8–5.4 g/dL), alpha-fetoprotein > 12,000 ng/mL
(normal < 77 ng/mL), and ferritin 1402 ng/mL (normal
15–150 ng/mL). The blood count was normal, and there
were no signs of infection (CRP 3.4 mg/dL, normal < 3
mg/dL). Blood gas analysis yielded an elevated lactate con-
centration of 6.1 mmol/L. Ammonia concentration was
123 μmol/L (normal < 70 μmol/L).

Abdominal ultrasound showed liver size at the upper
normal limit with enhanced echogenicity. No splenomegaly
was detected, and the gall bladder as well as the bile ducts
were normal. Polymerase chain reaction (PCR) analyses for
CMV, enterovirus and parechovirus were negative, and
toxoplasmosis was excluded serologically. Immunological
investigations were not suggestive for immunological
causes of the hepatopathy. Elastase concentration in stool
was normal, and newborn screening for cystic fibrosis was
unremarkable. Ultrasound of the brain, electrocardiogram
and echocardiography were unremarkable.

During the following days the child displayed recur-
rent episodes of asymptomatic severe hypoglycemia with
minimal glucose concentrations of 1.3 mmol/L despite
frequent feeding (every 2 h). Lactate concentrations ranged from 0.9 to 6.1 mmol/L.

Metabolic investigations were interpreted as not sug-
gestive of a specific disorder. Organic acids in urine
showed massive tyrosuria, well compatible with hepa-
topathy. Acylcarnitine analysis in dried blood spots
yielded an elevated concentration of free carnitine with
unspecifically elevated levels of several acylcarnitines.
Amino acid analysis showed elevated concentrations of
several amino acids including citrulline (331 μmol/L,
normal < 35 μmol/L). The sialotransferrin pattern
(screening for congenital disorders of glycosylation) was
normal.

Due to the trias of hepatopathy/impaired hepatic func-
tion, lactic acidosis and recurrent hypoglycemia a hep-
atic form of a mitochondrial depletion syndrome was
initially suspected, especially in combination with the
markedly elevated concentrations of alpha fetoprotein
and ferritin. Clinically, no neurologic involvement was
observed, and the brain MRI showed unremarkable re-
sults. To prevent hypoglycemia breast milk was supple-
mented with MCT oil and maltodextrin. After 2 weeks,
the child had to be transferred to the intensive care unit
due to severe recurrent hypoglycemia. In the end, nor-
mal blood glucose levels could only be achieved by con-
tinuous i.v. glucose infusion or continuous oral feeding.
Therefore, a percutaneous endoscopic gastrostomy
(PEG) tube was inserted to enable normoglycemia and
discharge from the hospital. Due to major PEG tube
complications and a suspected intestinal perforation
followed by a systemic infection inpatient treatment was
prolonged. Lactate levels during this episode increased
to 17 mmol/L. In the meanwhile, results of trio exome
sequencing became available and revealed two mutations
in the SLC25A13 gene, one frameshift variant c.852_
855del, p.Met285Profs*2 and a novel deletion c.(69 + 1_70–1)_(212 + 1_231–1)del, p.? The father was found heterozygous for the frameshift variant by Sanger sequencing, whereas the mother is a carrier of the deletion, confirmed by qPCR.

Since several attempts to implement tube-feeding with tea or small amounts of breast milk resulted in severe deterioration of abdominal symptoms, the PEG tube was removed after 3 weeks. Explorative laparotomy revealed extensive adhesions of the small intestine but no perforation. After removal of the PEG tube, the clinical condition stabilised and oral feeding could successfully be reintroduced. The child received a galactose-free, carbohydrate-reduced, MCT-enriched diet consisting of Pregomin Proexpert (Milupa) and Basic–ch (Nutricia) (composition of nutrients displayed in Fig. 1). Under this regimen blood glucose levels remained stable with feeding intervals of 4 h. Hepatopathy and cholestasis resolved apart from a persistent mild elevation of transaminase activities. Lactate levels also normalised. At the age of 4 months the patient could be discharged from hospital in good clinical condition. Blood glucose monitoring at home revealed no further hypoglycemia.

At the age of 6 months, supplementary foods were started without any complications. The diet was still galactose-free, carbohydrate-reduced and rich in protein and MCT. The girl is now 2 years old and shows normal psychomotor development. The only pathological findings are slightly elevated transaminase activities. Relevant laboratory parameters during the course of the disease are shown in Fig. 2.

**Patient 2**

One year later her younger brother was born. Genetic testing was initiated immediately after birth. Until the results became available, a diet consisting of 50% breast milk and 50% Pregomin Proexpert (lactose-free, 50% MCT fat) was recommended. On day 12, CD was genetically confirmed by Sanger sequencing for the paternal mutation and qPCR for the maternal mutation. A lactose-free, MCT-enriched diet was started on the same day. He clinically remained asymptomatic with no signs of cholestasis or icterus. Laboratory monitoring was performed at age 4, 7, 13 and 18 weeks. Results of liver enzymes, bilirubin and total protein concentrations are displayed in Fig. 3.

**Newborn screening**

CD is not a target disease of newborn screening programs in Germany. Nevertheless, citrulline levels as well as the levels of other diagnostic amino acids are measured in dried blood spots. Results of the amino acids measured by tandem mass spectrometry in the dried blood spots of the newborn screening samples of our two patients are displayed in Table 1.

**Discussion and conclusions**

We report on 2 siblings with compound heterozygosity for two variants in the SLC25A13 gene of whom the index patient presented with cholestasis at age 8 weeks while in the younger brother clinical symptoms were possibly prevented by early initiation of a specific diet. The main findings in our patient apart from hepatopathy were severe recurrent hypoglycemia and elevated lactate concentrations. Both hypoglycemia and hyperlactatemia are no common biochemical abnormalities in patients with NICCD [11], although hypoglycemia has been reported in few patients [12, 16, 18, 19]. The pathophysiology of hypoglycemia in CD is not well understood. Young children are prone to develop hypoglycemia relatively easily due to CD-related suppression of gluconeogenesis [20]. It has additionally been suggested that severe hypoglycemia in patients with CD could be associated with relatively low levels of ketone bodies, implying that β-oxidation and ketogenesis in these patients might possibly be partially disrupted [19] due to altered redox states and PPAR dysregulation. The diagnosis of CD in our patient 1 was slightly delayed as the clinical
picture was primarily suggestive of a hepatic form of a mitochondrial depletion syndrome, in particular DGUOK deficiency due to the markedly elevated levels of alpha fetoprotein and ferritin [21], and diagnosis was finally made by whole exome sequencing. Of the two mutations found in our patient, the c.852_855del, p.Met285Profs*2 variant is very common in Asian populations and derived from the father who was of Vietnamese origin [19, 22–24].

The second mutation, c.(69 + 1_70–1)_(212 + 1_231–1)del, has not been described previously, and the consequences of this variant on protein level are not known. However, since the deletion encompasses exon 3 of the SLC25A13 gene, it is well conceivable that this variant is deleterious. In Europe, CD is an extremely rare inborn error of metabolism. However, globalisation and the concomitant worldwide spread of Asian populations will increase the likelihood of identifying more cases of NICCD outside the classical distribution area for CD [25]. This highlights the importance for pediatricians and metabolic physicians of being aware of CD as a differential diagnosis of neonatal cholestasis.

NICCD usually responds very well to dietary treatment and clinical symptoms resolve within months. This was also true for our patient 1 who showed an immediate response to dietary adaptations with resolution of hypoglycaemia and cholestasis. Nevertheless, few severe (requiring liver transplantation) or even fatal cases have been reported [13–15, 26, 27]. Abuduxikuer et al. investigated a cohort of 61 confirmed NICCD cases for risk factors associated with mortality [27]. Comparing 52 cases in the survival group with 9 fatal cases of NICCD the authors identified late referral, presence of infection, delayed treatment with lactose-free/MCT formula, lower platelet count, lower levels of gamma-GT, total cholesterol and blood citrulline and higher blood concentrations of ammonia and tyrosine as factors associated with poor prognosis [27].

Most patients with CD show a particular food preference from early childhood with a natural aversion against carbohydrate-rich foods and a strong preference for protein- and fat-rich foods, which is very different from the well-known aversion to protein among patients with other urea cycle defects [1, 16]. Saheki et al. studied the food intake of 18 Japanese citrin-deficient subjects with an age range from 1 to 33 years [4]. They found that the average relative fat and protein intake was higher in CD patients compared with published values for the general Japanese population with 134 and 116%, respectively. In contrast, the average relative carbohydrate intake was only 56% of age- and sex-matched Japanese controls. Carbohydrate, fat and protein provided 37, 44 and 19% of total energy in CD patients compared to 56, 27.5 and 14.5% in the healthy population. The
peculiar food preferences may start from as early as 1 year of age, but they can take some time to be recognized by caregivers [4]. Nevertheless, food preferences may be a diagnostic hint for CD, even in the absence of other signs and symptoms [4, 19] and should prompt clinicians to rule out CD [4, 19].

Studies in animal models of CD have provided insights into possible mechanisms for reduced carbohydrate intake. Double knockout mice for mitochondrial glycerol-3-phosphate dehydrogenase and citrin, a phenotypic model for human CD, showed oral aversion to dietary sugar, ethanol and glycerol that correlated with alterations in specific hepatic metabolites [28]. The authors conclude that the aversion observed in the double-KO mice is mediated by hepatic metabolic perturbations, resulting in a behavioral response to

![Fig. 3](image)

**Fig. 3** Laboratory parameters in the clinical course of patient 2 from birth until the age of 18 weeks

| Parameter | Patient 1 | Patient 2 | Reference range (μmol/L) |
|-----------|-----------|-----------|--------------------------|
| citrulline (μmol/L) | 49        | 51        | 6–91.63                  |
| tyrosine (μmol/L)  | 49        | 32        | < 350                    |
| phenylalanine (μmol/L) | 38        | 32        | < 123                    |
| alanine/citrulline ratio | 3.18 | 3.86 | n.a.                     |
increased hepatic cytosolic NADH and a decreased cellular adenine nucleotide pool [28]. The same findings may underline the dietary predilections observed in CD patients. Under normal conditions, an increase in cytosolic NADH/NAD+ ratio following a carbohydrate-rich meal is relieved by NADH shuttle activity via the malate-aspartate and/or glycerol phosphate shuttles. Saheki et al. postulated that in CD patients the citrin defect leads to inhibition of ureagenesis by limiting the supply of aspartate for the urea cycle. This is not only due to the lack of aspartate supplied from mitochondria, but also because a high cytosolic NADH/NAD+ ratio reduces the cytosolic oxaloacetate concentration resulting in a shortage of cytosolic aspartate [4]. By reducing the intake of carbohydrates, CD patients can effectively minimize this deficiency of aspartate [4]. These pathophysiological considerations explain why some of the conventional treatment procedures for urea cycle defects/hyperammonemia may be very harmful in individuals with CD. A low-protein carbohydrate-rich diet is the standard therapy of urea cycle defects. However, if given to a patient with CD, this may cause severe metabolic disturbances such as hyperammonemia and hyperlipidemia [18, 29]. Similarly, high glucose or glycerol infusions (i.e. for brain edema) may result in severe clinical deterioration or even death in patients with CTNL2 [30–32]. Mutoh et al. reported that some Japanese children with CD have become severely ill after the entrance into primary school, where all school children had to take a high-carbohydrate lunch provided by the school [33]. These examples underline the importance of caregivers to respect the CD-typical food preferences to avoid clinical decompensations.

Tandem mass spectrometry-based newborn screening for CD is performed in certain countries with a high incidence of CD [34, 35]. Elevated citrulline levels and several citrulline-based ratios are the primary screening markers. However, it is known that citrulline levels in children with NICCD may not be elevated immediately after birth and several cases missed by newborn screening have been reported [13, 19, 36]. In a recent study with 55 patients with genetically proven NICCD, only 18 cases (18/55, 32.7%) were true positives and 37 cases (37/55, 67.3%) were false negatives based on the cut off value for citrulline in dried blood spots in newborn screening [35]. Blood sampling time seems to have an influence on the sensitivity of NICCD newborn screening, and false negative results were more common in the group of very early-screened patients. The citrulline levels in the newborn screening samples of our two patients were also normal. However, as CD is not a target disease of German newborn screening programs, cut off values established for the diagnosis of citrullinemia type 1 were used in our patients (displayed in Table 1) [37]. Clinical laboratory studies from countries with high incidence of CD have established lower cut-off values for citrulline in newborn screening [34, 38]. To improve the detection rate of NICCD in newborn screening the combined use of low citrulline cut offs together with second tier genetic screening has been suggested as the optimal strategy [34].

Since the treatment of citrullinemia type 1 and CD are very different and a protein-reduced, carbohydrate-enriched diet as suggested in citrullinemia type 1 aggravates symptoms in CD, a clear discrimination is essential directly after the newborn screening results have become available. This is sometimes challenging since mild forms of citrullinemia type 1 may only present with elevated citrulline without elevation of glutamine.

As CD is a well-treatable disorder this metabolic defect should be ruled out early in every infant with hepatic cholestasis and should also be considered in screened patients with mild elevations of citrulline. It is important to recognize that hypoglycemia can be part of the biochemical phenotype and that the clinical presentation may mimic hepatic mitochondrial depletion syndrome.

Abbreviations
CD: Citrin deficiency; NICCD: Neonatal intrahepatic cholestasis caused by citrin deficiency; MCT: Middle-chain triglycerides; PCR: Polymerase chain reaction; PEG: Percutaneous endoscopic gastrostomy

Acknowledgements
This work was supported in part by the Center for Metabolic Diseases, Freiburg Center for Rare Diseases. Several authors of this publication are members of the European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN) – Project ID No 739543.

Authors’ contributions
SG was responsible for the diagnostic work-up and treatment of both patients and drafted the manuscript including all tables and Figs. AS, SRF, MS, HS, HF, JT, LH and US were involved in the diagnosis and/or clinical care of the patients and critically revised the manuscript. PF gave advise in the diagnostic process and management of the patient. SBW and AJM performed whole exome screening and interpretation of the results. TBH supervised the molecular work. GG performed newborn screening in both patients. All authors read and critically revised the manuscript.

Funding
Not applicable. Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
The patients’ parents gave their written informed consent for the publication of this report.

Competing interests
The authors declare that they have no competing interests.
Author details

1Department of General Paediatrics, Adolescent Medicine and Neonatology, Medical Centre-University of Freiburg, Faculty of Medicine, Mauthildenstraße 1, 79106 Freiburg, Germany. 2Department of Paediatrics, Nikulm Reutlingen, 72764 Reutlingen, Germany. 3Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. 4Center for Rare Diseases, University of Tübingen, 72076 Tübingen, Germany. 5University Hospital Heidelberg, Centre for Paediatric and Adolescent Medicine, Division of Neuropaediatrics and Metabolic Medicine, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany. 6Department of General Paediatrics, Adolescent Medicine and Neonatology, Laboratory of Clinical Biochemistry and Metabolism, Medical Centre-University of Freiburg, Faculty of Medicine, Freiburg, Germany.

Received: 4 September 2020 Accepted: 30 October 2020
Published online: 11 November 2020

References

1. Saheki T, Inoue K, Tushima A, Mutoh K, Kobayashi K. Citrin deficiency and current treatment concepts. Mol Genet Metab. 2010;100(Suppl 1):S59–64.
2. Saheki T, Song Y-Z. Citrin deficiency. In: Adam MP, Arlingder HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews®. Seattle, Washington: University of Washington, Seattle; 1993. http://www.ncbi.nlm.nih.gov/books/NBK1181/. Accessed 7 Mar 2020.
3. Saheki T, Kobayashi K. Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrininemia (CTLN2) and idiopathic neonatal hepatitis (NICCD). J Hum Genet. 2002;47:333–41.
4. Saheki T, Kobayashi K, Terazaki M, Ohtsu T, Yaozawa Y, Okano Y, et al. Reduced carbohydrate intake in citrin-deficient subjects. J Inherit Metab Dis. 2008;31:86–94.
5. Palmieri L, Pardo B, Lasorsa FM, del Arco A, Kobayashi K, Iijima M, et al. Citrin and aralar1 are Ca(2+)-stimulated aspartate/glutamate transporters in mitochondria. EMBO J. 2001;20:5060–9.
6. Dimmock D, Maranda B, Dionisi-Vici C, Wang J, Kleppe S, Fiermonte G, et al. Citrin deficiency, a perpleting global disorder. Mol Genet Metab. 2009;96:64–9.
7. Dimmock D, Kobayashi K, Iijima M, Tabata A, Wong L-J, Saheki T, et al. Citrin deficiency: a novel cause of failure to thrive that responds to a high-protein, low-carbohydrate diet. Pediatr. 2007;119:e73–7.
8. Ben-Shalom E, Kobayashi K, Shagag A, Yasuda T, Gao H-Z, Saheki T, et al. Infanile citrininemia caused by citrin deficiency with increased dibasic amino acids. Mol Genet Metab. 2002;77:202–8.
9. Hutchin T, Preece MA, Hendriez C, Chakrapani A, McClelland V, Okumura F, et al. Neonatal intraintrahepatic cholestasis caused by citrin deficiency (NICCD) as a cause of liver disease in infants in the UK. J Inherit Metab Dis. 2009;32(Suppl 1):S51–5.
10. Fiorente G, Soon O, Chaudhari A, Paradies E, Lee PJ, Krywawych S, et al. An adult with type 2 citrininemia presenting in Europe. N Engl J Med. 2008;358:1408–9.
11. Wang J-S, Wang Z-L, Wang J-S. The molecular epidemiology of citrin deficiency. Zhonghua Er Ke Za Zhi. 2019;57:788–95.
12. Saheki T, Inoue K, Ono H, Fujimoto Y, Furue M, Yamaura K-I, et al. Oral avarion to dietary sugar, ethanol and glycerol correlates with alterations in specific hepatic metabolites in a mouse model of human citrinin deficiency. Mol Genet Metab. 2017;120:366–16.
13. Imamura Y, Kobayashi K, Shibatou T, Aburada S, Tahara K, Kubozono O, et al. Effectiveness of carbohydrate-restricted diet and arginine granules therapy for adult-onset type II citrininemia: a case report of siblings showing homozygous SLC25A13 mutation with and without the disease. Hepatol Rep. 2003;6:268–72.
14. Takahashi H, Kagawa T, Kobayashi K, Hiraibayashi H, Yui M, Begum L, et al. A case of adult-onset citrin deficiency–deterioration of clinical course after infusion of hyperonotic and high sugar solutions. Med Sci Monit. 2006;12:CS13–9.
15. Yazaki M, Takei Y, Kobayashi K, Saheki T, Ikeda S. Risk of worsened encephalopathy after intravenous glycerol therapy in patients with adult-onset type II citrininemia (CTLN2). Intern Med. 2005;44:188–95.
16. Fukushima K, Yazaki M, Nakamura M, Takata N, Kobayashi K, Saheki T, et al. Conventional diet therapy for hyperammoninemia is risky in the treatment of hepatic encephalopathy associated with citrin deficiency. Intern Med. 2010;49:243–7.
17. Mutoh K, Kurokawa K, Kobayashi K, Saheki T. Treatment of a citrin-deficient patient at the early stage of adult-onset type II citrininemia with arginine and sodium pyruvate. J Inherit Metab Dis. 2008;31(Suppl 2):S234–7.
18. Lin Y, Liu Y, Zhu L, Ke L, Shen Y, Yang C, et al. Combining newborn metabolic and genetic screening for neonatal intraintrahepatic cholestasis caused by citrin deficiency. J Inherit Metab Dis. 2010;33:430–7.
19. Fang CF, Liu SC, Feng Y, Mei HF, Liu HP, Feng JW, et al. Newborn screening program and blood amino acid profiling in early neonates with citrinin deficiency. Zhonghua Ke Xue Za Zhi. 2019;57:797–801.
20. Estrella J, Wilcken B, Carpenter K, Bhattacharya K, Tchan M, Wiley V. Expended newborn screening in New South Wales: missed cases. J Inherit Metab Dis. 2014;37:881–7.
21. Sandor J, Janzen N, Sander S, Steuerwald U, Das AM, Scholl S, et al. Neonatal screening for citrininemia. Eur J Pediatr. 2003;162:217–20.
22. Tamamori A, Fujimoto A, Okano Y, Kobayashi K, Saheki T, Tagami Y, et al. Effects of citrin deficiency in the perinatal period: feasibility of newborn mass screening for citrinin deficiency. Pediatr Res. 2004;56:608–14.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.